安必平: 关于2025年半年度募集资金存放与实际使用情况的专项报告

Fundraising Overview - The company raised a total of RMB 71,327.04 million from the issuance of 23.34 million shares at a price of RMB 30.56 per share, with a net amount of RMB 63,994.55 million after deducting issuance costs of RMB 7,332.49 million [1][2] - As of June 30, 2025, the remaining balance of unused raised funds is RMB 12,935.19 million, which includes RMB 235.19 million in the fundraising account and RMB 12,700.00 million in time deposits and financial products [2][3] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure the effective management and use of raised funds, including the establishment of dedicated bank accounts for fundraising [2][3] - The company signed tripartite and quadripartite supervision agreements with its subsidiaries and the sponsoring institution to clarify the rights and obligations of all parties involved [2][3] Fund Usage - The company has not used idle raised funds to temporarily supplement working capital during the reporting period [4][5] - The company has approved the use of up to RMB 16,000 million of idle raised funds for cash management, ensuring that it does not affect the normal progress of fundraising investment plans [5][6] - As of June 30, 2025, the company has invested RMB 12,700.00 million in various financial products, including transferable large-denomination certificates of deposit and structured deposits [5][6] Project Investment - The company has not made any early investments or replacements for fundraising investment projects during the reporting period [7] - The company has approved the use of part of the raised funds for new projects, including the development of a tumor companion diagnostic technology platform and a digital pathology and intelligent application development project, with an estimated investment of RMB 6,350.00 million [5][6] Remaining Funds - The company has a remaining balance of RMB 10,732.55 million in excess raised funds, which is not applicable for permanent working capital supplementation or loan repayment [6][7]